4.0
Feb 14, 2017
Anonymous employee
Former employee, more than 10 years
Recommend
CEO approval
Business Outlook
Pros
The people are great. The greatest loss for me will be not working with my colleagues anymore.
Cons
Pipeline falling short of expectation. Since losing the three largest contribution product patents, there has been little to make up for the loss. Diabetes portfolio is a performing poorly, Advair will soon be generic which means respiratory market will erode for Symbicort and the Oncology products -though innovative- can't make up the $$.